The problem of the oetiology of the disease process at work in the central nervous system, and possibly elsewhere, in patients with multiple sclerosis is being attacked from many different angles, and it is attracting the attention not only of clinicians and pathologists, but also of epidemiologists, geneticists, biochemists, biophysicists and even geophysicists.
Being a biochemist, I will largely limit myself to what I regard as a hopeful biochemical approach, although I shall touch, albeit as an amateur and with some trepidation, on various fields more expertly covered by these other specialists.
The chief question which I want to discuss is the cause and the nature of the process that brings about the disintegration of localized, scattered areas of the myelin sheaths of nerve fibres running within the white matter of the central nervous system. Linked with this are two further questions, namely, why are these lesions so scattered both in time and in their localization, and why should the incidence of this disease be so relatively frequent in certain parts of the world, and so infrequent in others?
The bizarre geographical distribution of multiple sclerosis has naturally led many to think of an infective cause, perhaps a virus. Variations of nutritional habits and exposures have also been invoked as another environmental factor that might operate to different extents in different areas of the world; in particular, the quantities of animal fats that are consumed have been proposed by Swank (Swank & Backer 1950 , Swank et al. 1952 , Swank 1961 and also by Sinclair (1956) as being related to the onset of the disease. The possibility of a trace metal deficiency has been considered, largely by analogy with the demyelinating conditions, swayback and enzootic ataxia, that can develop in lambs as a result of copper deficiency, but as far as I am aware no clear-cut evidence has as yet been produced indicating that copper deficiency in man is in any way associated with multiple sclerosis (Mandelbrote et al. 1948 , Plum & Fog 1959 . The experimental production of a so-called 'allergic encephalomyelitis' by the injection into laboratory animals of suitable extracts of brain, together with the finding of an increased level of yglobulins in the cerebrospinal fluid in many patients with multiple sclerosis, has given rise to the widely held view that this disease may be the expression of some immune or autoimmune process occurring in the central nervous system. Localized cerebral anoxia, possibly due to localized thrombotic occlusion of small blood vessels in the brain and spinal cord, as suggested by Putnam (1937) , has also been proposed as the underlying change responsible for the development of the plaques of multiple sclerosis.
But apart from the underlying oetiology of the condition which has given rise to these many and varied theoriesand there are others that I have not mentionedthe mechanism of the break up of the myelin sheaths would seem to be an essentially biochemical problem, which, in view of our present knowledge of the chemical nature of the myelin sheath, should be susceptible to laboratory investigation. Indeed one of the earliest theories put forward to account for the development of the plaques seemed to my colleagues and me at Guy's Hospital positively to invite investigation by modern biochemical methods.
Marburg in 1906 had put forward the view that the plaques might be due to an enzymic lysis of myelin. A study of the enzyme systems present in nerve cells and glial cells, and also of other nonenzymic means by which the lipids and proteins of the myelin sheath might be attacked and degraded, seemed therefore to be urgently required.
Phospholipid Metabolism
We began this phase of our study of multiple sclerosis by an examination of the breakdown of phospholipids in the central nervous system. Our reasons for beginning with this particular type of substance were that nervous tissue is particularly rich in phospholipids, and also that the breakdown of these compounds can give rise to the production of lysophosphatides, of which lysolecithin is the best known example. This is the powerfully hiemolytic substance which, as was shown by Delezenne & Ledebt in 1911 , is formed from lecithin by the action of an enzyme, phospholipase A, present in many snake venoms. This conversion of an essential component of cell membranes into a cytolytic substance is brought about as the result of the removal of one of the two fatty acids present in the lecithin molecule by the enzyme phospholipase A. The particular fatty acid, joined on to the central carbon atom of the glycerol portion of the lecithin molecule, which is removed in this conversion to lysolecithin is an unsaturated fatty acid.
A further reason for studying the metabolism of this group of phospholipids in the nervous system was provided by the demonstration by Morrison & Zamecnik (1950) in America that both lysolecithin and phospholipase A can, when added to excised portions of spinal cord, cause demyelinating changes to appear, a finding which was confirmed by Birkmayer & Neumayer in Vienna in 1957. It is indeed now clear that, in addition to its himolytic activity, lysolecithin can also bring about the lysis of nerve cells and glial cells, and can cause, the break up of myelin, rendering it freely soluble in aqueous media.
It seemed important, therefore, to know whether lysolecithin is a normal component of brain tissue. If this should be so, it might be expected that the amount of this potentially toxic compound would normally be kept to low concentrations by its further metabolism, or that it would be held in some 'fixed' and non-toxic form. But if the rate of its formation in brain tissues were increased, or if its metabolism were altered so as to allow its accumulation, then damage to the central nervous system might be expected.
As long ago as 1932 Pighini in Italy had obtained a fraction from human brain which, from its solubility properties and its biological actions, appeared to resemble a lysophosphatide. Using more modern methods of fractionation on silicic acid, Dr Webster, Dr Niemiro and I were able to isolate and identify lysolecithin as what we b2live to be a physiologically occurring component of normal human brain, although present, as might be expected perhaps, in very small amounts (Thompson et al. 1960, Webster & 1962) . Brain tissue has now also been shown to contain enzymes which can produce lysolecithin from lecithin, and which can break down lysolecithin to give nonhiemolytic, nontoxic compounds (Gallai-Hatchard et al. 1962) . Table 1 shows how lecithin slowly disappears and how lysolecithin accumulates when suitably prepared extracts of brain are incubated with lecithin. These experiments were carried out by extracting and separating the various phospholipids chromatographically after incubation of the brain extract with lecithin. The lecithin and lysolecithin were then estimated either by determination of phosphorus, or by using radioactive lecithin and measuring the radioactivity of the separated fractions.
In addition, it has been shown that brain tissue contains other enzymes, which can convert lysolecithin into the nontoxic glycerylphosphorylcholine (Marples & Thompson 1960) by splitting off the single fatty acid present in the lysolecithin molecule, or which can add on a second fatty acid to lysolecithin to re-convert it to lecithin .
The next logical step in the application of these purely biochemical observations to the problem of multiple sclerosis would be to determine whether lysolecithin can be shown to be present in abnormal amounts in the central nervous system in this disease, or whether there exists any abnormality of these various enzymes concerned in its metabolism. Unfortunately, the pathology of this disease and the technical difficulties involved in determining quantitative variations in the levels and activities of these substances render this difficult, and these measurements have not yet been made.
It did, however, seem possible to determine experimentally whether a derangement of these enzyme systems, such as would occur in brain tissue exposed to anoxia, would lead to the accumulation of lysolecithin, which in turn could cause further damage to membrane structures in the tissue. Slices of rat brain were therefore incubated for varying periods of time, some in an atmosphere of oxygen, and some in nitrogen. Lipid fractions containing the lysolecithin were then prepared from the slices and the lysolecithin estimated. The results of these experiments are shown in Table 2 .
It will be seen that in each of the four experiments listed there is a considerable increase in the lysolecithin present in the brain slice as a result of incubation in vitro, and in each case, in the presence of nitrogen, the anoxic slice shows an appreciably greater accumulation (Webster & Thompson 1965) .
If, therefore, as more than one of the aetiological theories to which I have referred suggests, localized cerebral anoxia is playing a part in the formation of the plaques in multiple sclerosis, it might be expected to give rise to localized accumulations of this cytolytic substance, which might extend or accentuate structural damage in or around the anoxic area.
Fatty Acid Studies A further approach to this problem rests on a study of the proportions of different fatty acids present in brain phospholipids, since the formation of lysolecithin from lecithin by the action of phospholipase A involves the removal of a fatty acid. Also, it has been recently shown by Witting and his colleagues (1961) and again by Mohrhauer & Holman (1963) that it is possible in the rat to alter the fatty acid composition of brain lipids quite strikingly by varying the levels of unsaturated fatty acids in the diet; in view of this, and bearing in mind the suggestions that have been made by Swank and others that changes in dietary fat intake may be related to the onset of the disease, it seemed possible that the kinds and Table 2 Increase in lysolecithin content (g,moles/g tissue) of brain slices on incubation under aerobic and anaerobic conditions (Reproduced from Webster & Thompson, 1965, proportions of the different fatty acids incorporated into the phospholipids in the central nervous system might be abnormal in multiple sclerosis. We therefore extracted the lecithin fraction from cerebral white matter from 6 normal brains and from 9 brains affected by multiple sclerosis. In each case care was taken to dissect from the pathological brain only those areas of white matter which were not in the immediate vicinity of a recognizable plaque, and which appeared normal on visual inspection. The proportions of the different fatty acids derived from these lecithin fractions were then determined by gas chromatography (Baker et al. 1963) . Table 3 shows the proportions of the five most plentiful fatty acids present in these lecithin fractions. The findings seem to indicate certain differences between the lecithins derived from normal and multiple sclerosis brains. It will be seen that there is a shift in the proportions of saturated and unsaturated fatty acids in the abnormal tissue, the saturated acids being increased, and the unsaturated acids decreased. One point of interest that would seem to emerge from these measurements is the indication that chemical differences may exist in apparently unaffected areas of brain tissue in multiple sclerosis. Such differences, possibly inborn in nature, might render the central nervous system more sensitive to other potentially damaging factors. There is perhaps an analogy here to the abnormal haemoglobin syndromes such as sicklecell anemia, or to favism where ingestion of the fava bean produces a hemolytic anmmia in The altered proportions of fatty acids which we found in these brains could be due to some purely local cause such as an abnormality of lecithin synthesis or degradation, possibly involving one of the enzymes I have been discussing, or it could arise as a result of some more general cause, such as a change in the relative amounts of saturated and unsaturated fatty acids reaching the brain.
A study of the blood lipids in multiple sclerosis seemed therefore to be the next step. The overall levels of cholesterol and of phospholipids in the blood in multiple sclerosis have, of course, been studied by many groups of workers for many years, and very conflicting reports have emerged. Very little work, however, has been done on the fatty acid components, and so Dr Baker, Dr Zilkha and I set out to study the percentage fatty acid composition of the total lipid extract of serum taken from a group of 47 patients with multiple sclerosis, and from 38 control subjects. Most of the cases of multiple sclerosis were inpatients at the National Hospital, Queen Square. The controls were either healthy subjects or inpatients suffering from other neurological disorders, but comparable as regards weight, sex, age and physical handicap.
The patients with multiple sclerosis were divided into four groups, depending on a clinical assessment of the activity of the disease, Grade I consisting of patients showing no evidence of clinical deterioration in their condition over the preceding month, Grades II, III and IV showing increasing evidence of recent deterioration. Blood was drawn from each subject after an overnight fast. The specimens were taken in pairs, one from a control subject and one from a patient with multiple sclerosis, and the subsequent analyses were carried out 'blind', the biochemists being unaware of the source of the specimen and of the grading attached to the patient.
The one striking change which was found was that the percentage of linoleic acid in the serum lipids was significantly reduced in the multiple sclerosis group taken as a whole. Furthermore, the percentage of this acid was found (Table 4) to Table 4 Percentage of linoleic acid (18: 2) in the total lipid extract of serum fall progressively with increasing evidence of recent deterioration in the patient's condition (Baker et al. 1964 ).
These figures of course only represent the proportion of linoleic acid in the serum lipids, and a fall in this proportion could result either from a reduction in the amount of linoleic acid, or from an increase in the amount of some other acid or acids in the serum.
The absolute amount of linoleic acid in the serum was therefore determined in 20 control subjects and 26 patients with multiple sclerosis (Baker et al. 1966 ). Since, as already pointed out, patients in the inactive phases of the disease -Grade Ishowed a normal percentage of linoleic acid, only Grades II, III and IV were used for these further determinations. The absolute level of linoleic acid, as well as the percentage, also shows a decided fall in patients with active multiple sclerosis (Table 5 ). It is of interest to note that none of the other fatty acids, either saturated or unsaturated, that are present as component parts of the serum lipids showed any deviation from the normal values.
Since, as has been shown by many groups of workers, the cholesteryl ester fraction contains a much higher proportion of linoleic acid than either the phospholipid or triglyceride fractions, the levels of cholesteryl linoleate have also been determined in a further series of patients, using an entirely different technique (Baker et al. 1965 ).
This later series of patients was subdivided into only three groups, A, B and C, of increasing activity. Table 6 shows the levels of cholesteryl linoleate in the serum of patients divided into three groups. Patients in Group A showed a mean level within the range found in healthy subjects, but, again, patients in Groups B and C, in whom there was evidence of moderate or extensive activity of the disease process, showed a substantial and statistically significant fall in the level of this ester.
From all these measurements that I have just described it seems therefore that the active phases of the disease, that is to say the times at or around which extension of existing plaques or the development of new plaques is occurring, are associated quite regularly and strikingly with a fall in the level of linoleic acid in the plasma, this fall manifesting itself most markedly by a fall in the level of cholesteryl linoleate.
A number of questions arise from these observations: (1) What is the cause of this fall of a blood constituent in this disease, the overt symptoms and signs of which are so strictly limited to the central nervous system? (2) Can this change be fitted in to the wider background of knowledge derived from clinical and epidemiological data? (3) What is the relationship and the connexion of these changes in plasma linoleate, occurring apparently only in patients in whom the disease is active, with the disease process in the central nervous system that results in local demyelination?
To return to the first of these questions, a fall in the level of plasma linoleate could clearly occur either as a result of a diminished entry of this fatty acid into the blood, or from an increased rate of its removal from the blood stream. Diminished entry into the blood could in turn arise either from a dietary deficiency or from a failure of absorption of this fatty acid.
A dietary deficiency of linoleic acid seems unlikely to account for the findings in the patients that we have studied: their general nutritional status was good, they were on a balanced and varied diet, and the 'neurological controls' were inpatients from the same hospital and the same wards as the majority of the multiple sclerosis patients, and were therefore taking essentially the same diet.
On the other hand, dietary habits are known to vary with climate and latitude, particularly with respect to the intake of saturated and unsaturated fatty acids and, as pointed out earlier, Swank (1961) has put forward the view that the high prevalence of multiple sclerosis in certain parts of the world may be related to the consumption of large quantities of animal fats. His evidence for this view is based on a number of epidemiological findings and conclusions, although it must be stressed that some of these observations are in need of confirmation using larger population groups, and some of the conclusions are not at present universally accepted. However, in 1952 Swank, Lerstad, Str0m and Backer carried out a study of the geographical distribution of multiple sclerosis in Norway; their work indicated that the incidence of new cases of this disease was low in the coastal fishing areas of Norway, but was high in the inland farming areas. These differences have since been confirmed by Presthus and Oftedal (quoted by Allison 1963) . Further, by means of field studies of the diets consumed by people in these coastal and inland areas Swank concluded that the butter and animal fat intake was distinctly higher in the farming than in the coastal fishing regions.
Evidence of a similar kind has more recently been obtained by Allison, in collaboration with Fog and Hyllested, with regard to the dietary habits and the incidence of multiple sclerosis in the Faroe Islands and in the Orkneys and Shetlands. Allison (1963) has found a crude prevalence rate for the Orkney and Shetland Islands of 152-7 per 100,000, as compared with 48'4 per 100,000 for the Faroes. That is to say, the incidence of the disease in the Faroes is certainly not high for a northern country, whereas the Orkney and Shetland Islands harbour an unusual concentration of cases, the incidence being certainly very much greater than any so far described for any other region of Europe or North America. Allison has, however, pointed out that while these islands, the Faroes on the one hand and the Orkneys and Shetlands on the other, differ little in latitude, longitude, annual hours of sunshine, rainfall and summer and winter temperature, there are striking differences in diet. The diet of the Orcadians and Shetlanders does not differ greatly from that of the rest of Great Britain, whereas that of the Faroe Islanders, consisting largely of whale meat, blubber, dried mutton, puffins, and much more fish, is a diet rich in unsaturated fatty acids. The high prevalence of the disease in the Orkneys and Shetlands, as compared with either the Faroes or with other parts of Great Britain certainly indicates that some factor other than a possible dietary one must be playing a part, but these epidemiological observations, like those of Swank's in Norway, are certainly consistent with the conception that the lack of availability of unsaturated fatty acids may be one factor associated with the development of this disease.
In his earlier writings Swank appears to have been thinking in terms of a high fat intake, although one consisting perhaps largely of animal fat, milk, butter, as being a potential causative factor. On the other hand it has been pointed out (McAlpine et al. 1955 ) that in this country patients with multiple sclerosis are not commonly known to exist on high-fat diets. Sinclair in 1956 was one of the first to stress the possible importance in multiple sclerosis of a deficiency of unsaturated fatty acids rather than an excess of animal fat per se, and our finding of low levels of serum linoleate in the active phases of the disease could be consistent with such a view. It must be remembered, however, that the evidence put forward by Peifer & Holman (1959 ), Holman (1961 and others, suggesting that a high intake of saturated animal fat may increase the requirement of essential polyunsaturated fatty acids, could mean that these two views need not be mutually exclusive.
There are of course a number of facts that can be cited which do not accord with these views concerning the importance of diets high in animal fat or poor in unsaturated fatty acids. Perhaps the most important of them is the extreme infrequency of the disease in white South Africans, which has still to be explained, since according to Bronte-Stewart (1955) the consumption of animal fat by this section of the South African community is high, and is probably quite comparable to that consumed in Northern Europe orin Canada or the United States.
Apart from dietary considerations, however, and since, as already pointed out, we have no reason to suspect that diet was playing any role in the patients that we have studied, the possibility of some defect in the intestinal absorption of polyunsaturated fatty acids has got to be remembered.
Among the many theories put forward to account for the etiology of multiple sclerosis, intestinal malabsorption has already been proposed. Shatin (1964) in Australia, also in an attempt to relate the geographical pathology of multiple sclerosis to its causation, has remarked on the association that he believes to exist between areas of high prevalence of the disease, and the consumption of cereal grains rich in gluten, and has put forward the view that an enteropathy, induced by gluten or by some other constituent of wheat, might result in an absorption defect, responsible ultimately for the development of central demyelination. It must be stressed, however, that this view rests flimsily on purely epidemiological and nutritional assessments, and is unsupported by clinical or experimental observations. Finally, before leaving the intestine, I would like to refer to a suggestion put forward recently by Professor Henry Miller and his colleagues in Newcastle (Poskanzer et al. 1963) . Struck by the similarity in geographical distribution, and in a number ofother epidemiological features, between multiple sclerosis and poliomyelitis, they have put forward the tentative hypothesis that multiple sclerosis may represent the occasional neurological manifestation of a widespread subclinical enteric infection by a virus, just as paralytic poliomyelitis is a rare neurological manifestation of infection with the poliomyelitis virus. Even although, unlike poliomyelitis, the postulated virus in multiple sclerosis might not gain access to the central nervous system, it might be that a viral infection of the intestine could result in an impairment of intestinal function and absorption.
We are certainly, therefore, not short of suggestions and hypotheses that have been put forward from time to time which might well account for the lowering of linoleate levels in the serum in the active phases of multiple sclerosis. And it is perhaps worth recalling that we have * only to think of subacute combined degeneration of the cord to find ourselves with another disease of the central nervous system resulting from a deficiency occasioned by a primary lesion in the gastrointestinal tract associated with a specific failure of absorption in the intestine. Now I would like to turn to the question of the relation of these changes in plasma linoleate to the development of localized and scattered areas of demyelination in the central nervous system. What clues have we as to the possible connexion between this lowering of plasma linoleate and the production of damage in the brain and spinal cord ?
One clue, which we are at present following up, appears to have been provided by some of the recent work dealing with the problems of atherosclerosis, particularly when this work is viewed in the context of some of the earlier theories which stressed the importance of vascular lesionsin particular microthrombotic lesionsin multiple sclerosis.
The multiple, scattered lesions in this disease immediately suggest the possibility of a vascular origin, and the anatomical relationship of blood vessels to small, early plaques has been studied intensively since the last century. Although there has been a prolonged controversy about this relationship, Lumsden (McAlpine et al. 1955) has concluded that the evidence does indicate the frequent presence of a small venule in the centre of the younger and smaller lesions. He states that while venules appear to have 'some influence in determining the sites of origin of the plaques, they do not determine the subsequent evolution or form of the plaque'.
The view that the plaque develops as the direct result of occlusion, probably due to thrombosis, of the central venule has been strongly championed by Putnam (1937) . However, I believe it is true to say that while many modern workers hold to the view that the majority of plaques originate around a small vein, the evidence for the presence in these venules of any well-formed, organized thrombus is scanty (Dow & Berglund 1942 , Zimmermann & Netsky 1950 .
More recently, however, it has been suggested that temporary occlusion of small blood vessels in the central nervous system resulting from agglutination and aggregation of blood platelets may be responsible. Putnam, in his paper in 1937, described thrombi in cerebral venules composed almost exclusively of platelets, and both Persson (1958) and Swank (1961) , and others, have stressed the possibility of their importance in the development of the lesions in multiple sclerosis. Nathanson & Savitsky (1954) appear to have been the first to study platelet adhesiveness in this disease and, although the method used by them to measure platelet stickiness is open to certain technical criticisms, they concluded from their measurements that platelet stickiness is increased during periods of activity of the disease, and returns to normal in the quiescent phases. Fog et al. (1955) , in the following year, claimed that in the active phases of the disease the number of circulating platelets tends to fall.
The presence of some factor or substance, possibly released from the brain or spinal cord, in multiple sclerosis, which induces increased platelet adhesiveness, is suggested from the work of Persson (1958) , who found that cerebrospinal fluid taken from patients in the active, progressive stages of the disease contained a platelet-agglutinating substance. And in 1964 Field & Caspary described some observations showing that the addition of an encephalitogenic factor, isolated from human brain, to plasma from patients with active multiple sclerosis causes increased platelet stickiness, although this did not occur when the factor was added to plasma from healthy persons, and occurred to only a very slight extent with the plasma from patients in the quiescent phases of multiple sclerosis. Unlike Nathanson & Savitsky, Field & Caspary did not find any increased inherent stickiness of the platelets in their patients during periods of activity of the disease, but only when the encephalitogenic factor was added; although in a more recent communication (Caspary et al. 1965 ) they now state that they are finding that the platelets do show increased adhesiveness in multiple sclerosis, even in the absence of the added brain factor.
Ischemic heart disease is the other condition in which thrombosis and disordered lipid metabolism have been invoked as causative factors in the pathogenesis of the lesions, and the late Dr Bronte-Stewart and his colleagues at the Medical Research Council's Atheroma Research Unit in Glasgow have recently been trying to find a link between these two factors. Since platelet aggregation is probably one of the initial processes in thrombus formation they studied the effect of different fatty acid-l1cithin sols, and of different phospholipids thems?lves on platelet aggregation (Kerr et al. 1965 ). Very briefly, they showed that when sols of saturated fatty acids, such as palmitic or stearic acid, in lecithin are added to plateletrich plasma, aggregation of platelets occurred. The mono-unsaturated oleate also caused aggregation, whereas sols of lecithin with linoleate, or linolenate, produced no platelet aggregation. Shore & Alpers (1963) have also noted differences between saturated and polyunsaturated fatty acids in their effect on platelets as judged by release of histamine, the saturated acids inducing platelet damage in contrast to the polyunsaturated fatty acids which cause little or no release of histamine from them.
Bronte-Stewart and his colleagues (Kerr et al. 1965 ) made the further interesting observation that the addition of a linoleate-lecithin sol, or of a linolenate-lecithin sol, to platelet-rich plasma before the addition of stearate-sol or palmitate-sol inhibited the platelet aggregation normally brought about by the saturated acid.
These observations, suggesting some form of protective action of these unsaturated fatty acids on the blood platelets, were of obvious interest to us in connexion with our finding of low levels of plasma linoleate in the active phases of multiple sclerosis, even although we have not as yet made any measurements of the free unesterified linoleate. We were anxious, therefore, to investigate again the question of platelet stickiness in this disease, and Dr Helen Payling Wright very kindly agreed during the summer to measure the platelet stickiness in a series of patients with active multiple sclerosis, and in a series of control patients from the same hospital, but suffering from nondemyelinating conditions (Wright et al. 1965) .
The results of these measurements are shown in Table 7 . There appears little doubt from these estimations that in these selected, acute, severe cases of multiple sclerosis the adhesiveness of the platelets is increased, and it is important that these observations should now be followed up by carrying out a furthzr series of platelet stickiness measurements, together with estimations of the level of cholesteryl linoleate in the plasma in order to determine to what extent a correlation between these two exists in patients with multiple sclerosis.
Finally, we have to consider how these various findings could be fitted together to give an etiological hypothesis which would be consistent with the pathology and natural history of the disease.
Let us take as a start the reduction in the level of linoleate in the plasma in the acute phases of the disease. This change in the blood chemistry is associated with, and is perhaps even responsible for, an increase in the adhesiveness of the blood platelets which could then cause clumping of the platelets and blockage of small venules, although perhaps only of transient duration. Since the increased platelet stickiness is a phenomenon presumably occurring in the bloodstream as a whole, it might be expected that the effects of these platelet microthrombi, if formed, would be widespread, and not restricted only to the central nervous system. It must be remembered, however, that in general the peripheral tissues have a relatively large extracellular space and a system of lymphatic drainage, whereas the extracellular space in the central nervous system is almost certainly small, and there is no lymphatic system in the brain or spinal cord.
The effects of even temporary blockage of small blood vessels may therefore be more profound in the central nervous system than in other tissues, since, in addition to the hypoxia resulting from the occlusion, the small extracellular space and the absence of lymphatic drainage will tend to minimize the dilution and the removal from the area of histamine, 5-hydroxytryptamine and other possibly cytotoxic compounds released from the platelet thrombi. Moreover, the local anoxic conditions resulting from the platelet microthrombi might be expected to cause a further release of cytotoxic compounds from the glial and other cells in the anoxic area, and we have indeed already shown that in brain tissue lysolecithin formation is increased under such conditions. This is, of course, only an elaboration of a working hypothesis that has been suggested before, and the only new aspect of it is that the finding of the reduction in plasma linoleate may provide a clue to account for the increase in platelet stickiness. But perhaps the hypothesis has the merit that much of it at any rate lends itself to verification by observation and experiment.
We are still, however, left with the unanswered problem as to the cause of the fall in plasma linoleate. And this brings us back to what seems to me to be an almost essential inclusion in any theory of the eatiology of multiple sclerosis, and that is the participation of some constitutional, inborn factor, which, in the presence of another environmental factoreither dietary or some other process, involving perhaps a defect in intestinal absorptionresults in some at present unknown way in a fall of plasma linoleate, which in turn leads to the series of other changes which I have described. In the light of present knowledge about inborn errors of metabolism one thinks in terms of a genetically determined enzyme fault, but here, so far as multiple sclerosis is concerned, one enters the realms of pure speculation.
It is clear that much remains to be done in this field before we can tie together the various pieces of evidence to give a coherent picture of the sequence of events involved in the development and progress of this disease, but perhaps these biochemical observations may help in pointing the way.
